|  |  |
| --- | --- |
|  |  AGREE-S Reporting Checklist |

Title of guideline: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Name of first author: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Sponsoring organization (if applicable): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

|  |  |  |  |
| --- | --- | --- | --- |
| **Section** | **Checklist item** | **✔︎** | **Reported in:****(page # or manuscript section)** |
| Protocol | 1. The guideline has been developed according to a protocol and the link to the protocol is provided.
 |  |  |
| Objective | 1. The overall objective(s) of the guideline is (are) specifically described.
 |  |  |
| Health question(s) | 1. The health question(s) covered by the guideline [patient, interventions/procedures, outcomes] are specifically described.
 |  |  |
| Methodological support | 1. The guideline reports on whether it was supported by a guideline development committee, including a guideline methodologist.
 |  |  |
| Stakeholder involvement | 1. Representation of professional groups and patients included in the guideline development group is reported.
 |  |  |
| Target users | 1. The target users of the guideline are specifically described.
 |  |  |
| Systematic review | 1. The methods that were used to search for evidence are clearly described.
 |  |  |
| Selection criteria | 1. The criteria for selecting the evidence are clearly described.
 |  |  |
| Strengths/limitations of evidence | 1. The strengths and limitations of the body of evidence are clearly described.
 |  |  |
| Patient/public input | 1. The views and preferences of the target population (patients, public, etc.) are reported.
 |  |  |
|  |
| **Section** | **Checklist item** | **✔︎** | **Reported in:****(e.g. page # or manuscript section)** |
| Formulation of recommendations | 1. The methods for formulating the recommendations are clearly described.
 |  |  |
| Link between evidence and recommendations | 1. The health benefits, side effects, and risks have been considered in formulating the recommendations.
 |  |  |
| Link between evidence and recommendations | 1. The link between the recommendations and the supporting evidence is explicitly reported.
 |  |  |
| Clarity of recommendations | 1. The recommendations are specific and unambiguous.
 |  |  |
| Alternative options | 1. The different options for management of the condition or health issue are clearly presented.
 |  |  |
| Identification of recommendations | 1. Key recommendations are easily identifiable.
 |  |  |
| Resource considerations | 1. The potential resource implications of applying the recommendations have been considered.
 |  |  |
| Practice variability | 1. The guideline discusses potential variability in surgical expertise of those performing the interventions/procedures.
 |  |  |
| Role of funder | 1. The role of the funding body is described.
 |  |  |
| Conflicts of interest | 1. Competing interests of guideline development group members are reported in detail.
 |  |  |
| Facilitators and barriers | 1. The guideline describes facilitators and barriers to its application.
 |  |  |
| Update | 1. A procedure for updating the guideline is provided.
 |  |  |
| Implementation | 1. The guideline provides advice and/or tools on how the recommendations can be put into practice.
 |  |  |
| Monitoring | 1. The guideline presents monitoring and/or auditing criteria.
 |  |  |

Copyright: The GAP Consortium